Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (PASSOS)
Steps Per Day Among Persons With Multiple Sclerosis: Variation by Demographic, Clinical, and Device Characteristics.
Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders.
IL1-β expression in multiple sclerosis.
The ICF as a framework to collect and interpret data on the extent and variety of disability in neurological conditions.
Intrathecal baclofen pump for spasticity: an evidence-based analysis.
[Local reactions to disease-modifying drugs: pathogenesis and relationship to clinical effectiveness.]
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Correlation analysis of visual analogue scale and measures of walking ability in multiple sclerosis patients.
B cell VLA-4-deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.
Incidence and distribution of extravascular compression of extracranial venous pathway in patients with chronic cerebrospinal venous insufficiency and multiple sclerosis.
Modulating effects of WT1 on interferon-β-vitamin D association in MS.
Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab.
Gait and jogging parameters in people with minimally impaired multiple sclerosis.
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.
Empyema presenting as lower extremity weakness.
Corticosteroid-responsive torticollis as a presenting symptom of multiple sclerosis.
Human oligodendrocytes in remyelination research.
2015 Multiple Sclerosis Experts Summit.
FDA warns about the risks of unproven surgical therapy for multiple sclerosis.
Epstein-barr virus: the path from association to causality for a ubiquitous human pathogen.
Protective and Detrimental Roles for Regulatory T Cells in a Viral Model for Multiple Sclerosis.
Physical fitness, walking performance, and gait in multiple sclerosis.
1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis.
Exercise therapy for fatigue in multiple sclerosis.
Pages
« first
‹ previous
…
356
357
358
359
360
361
362
363
364
…
next ›
last »